Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BURLINGAME, Calif.--(BUSINESS WIRE)--Jun. 3, 2024-- Innoviva, Inc. (Nasdaq: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on Monday, June 10, 2024 at 1:20 p.m. Eastern Time.
Innoviva，Inc.（纳斯达克：INVA）（以下简称“Innoviva”或“公司”）是一家多元化控股公司，拥有一项核心版税组合，即领先的重症护理和传染病领域的Innoviva专业治疗（“IST”），以及在医疗保健资产领域的战略投资组合。今天宣布，总裁兼首席执行官Pavel Raifeld将于2024年6月10日星期一下午1:20在佛罗里达州迈阿密的高盛第45届年度全球医疗保健大会上参加炉边聊天。
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at https://investor.inva.com/presentations-events. The webcast will be available for replay for 90 days following the event.
在公司网站的投资者关系部分下的“事件和演示文稿”中可以查看炉边聊天的现场网络播放。https://investor.inva.com/presentations-events。现场网络播放将在活动结束后的90天内提供回看。网络直播将在活动结束后的90天内提供回放。
About Innoviva
关于Innoviva
Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets. Innoviva's royalty portfolio includes respiratory assets partnered with Glaxo Group Limited ("GSK"). Innoviva is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Innoviva's other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults.
Innoviva是一家多元化的控股公司，拥有一项核心版税组合，即领先的重症护理和传染病领域的Innoviva专业治疗（“IST”），以及在医疗保健资产领域的战略投资组合。Innoviva的版税组合涵盖了与Glaxo Group Limited（“GSK”）合作的呼吸资产。Innoviva有权从GSK那里收取RELVAR/BREO ELLIPTA和ANORO ELLIPTA的销售版税。Innoviva的其他创新医疗保健资产包括从Entasis Therapeutics收购的传染病和重症护理资产，包括用于治疗因易感株的Acinetobacter baumannii-calcoaceticus复合物引起的成人院内获得性细菌性肺炎和呼吸机相关细菌性肺炎的注射用sulbactam和durlobactam共包装的XACDURO，以及目前正在开发用于治疗不合并淋菌病的zoliflodacin，以及来自La Jolla Pharmaceutical Company的GIAPREZA（血管紧张素II），用于提高成人败血症或其他分布性休克患者的血压，以及XERAVA（eravacycline），用于成人复杂腹腔感染的治疗。鲍曼不动杆菌-肠杆菌复合体。这包括为治疗非淋菌性尿道炎而研发的特立氟磺胺和正在研发中的佐利福单以及洛杉矶制药公司，包括用于增加成人感染性休克或其他分布性休克患者的血压的血管紧张素II（GIAPREZA）和用于治疗成人复杂腹腔感染的埃拉霉素（XERAVA）。
ANORO, RELVAR and BREO are trademarks of the GSK group of companies.
ANORO，RELVAR和BREO是GSK公司集团的商标。
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603242707/en/
在businesswire.com上查看原始版本businesswire.com: https://www.businesswire.com/news/home/20240603242707/en/
Investors & Media:
Argot Partners
(212) 600-1902
innoviva@argotpartners.com
投资者和媒体：
阿哥特合伙人。
(212) 600-1902
innoviva@argotpartners.com
Source: Innoviva, Inc.
来源：Innoviva，Inc。